About Dr Samantha Ginn

Using cutting-edge gene transfer and genome editing technologies to treat mouse models of human disease.

The Gene Therapy Research Unit is working on developing new therapies for the treatment of genetic and acquired diseases of the liver and haematopoietic system. We have a diverse selection of projects available that can be tailored for both honours or PhD programs. All projects focus on the development and use of gene transfer and genome editing technology with a focus on targeting organs including the liver and bone marrow, both of which have immense promise as target organs for the treatment of genetic disease in children. The Gene Therapy Research Unit, led by Professor Ian Alexander, became the first team in Australia to treat a genetic disease (SCID-X1) by gene therapy and are recognised leaders in the establishment of this exciting field in Australia.

Dr Samantha Ginn is a researcher at the Children’s Medical Research Institute (CMRI) in Sydney, Australia. She is involved in international collaborations that aim to develop therapies for primary immunodeficiency and metabolic genetic disorders.  She is the current Secretary of the Australasian Gene and Cell Therapy Society and sits on Institutional Committees for Animal Care and Ethics, Grants Advisory, Early Career Researchers (ECRs) and Gender Equity. Dr Samantha Ginn has received a Young Investigator Award from the Australasian Gene and Cell Therapy Society and has been invited to present her work at the British Society of Gene and Cell Therapy and European Society of Gene and Cell Therapy annual meetings.

<html />

Selected publications

For a full list of Dr Ginn's publications, please see her university profile page (http://sydney.edu.au/medicine/people/academics/profiles/samantha.ginn.php)